Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Mecbotamab vedotin by BioAtla for Cervical Cancer: Likelihood of Approval
Mecbotamab vedotin is under clinical development by BioAtla and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
Mecbotamab vedotin by BioAtla for Pancreatic Cancer: Likelihood of Approval
Mecbotamab vedotin is under clinical development by BioAtla and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of BioAtla's Mecbotamab vedotin?
Mecbotamab vedotin is a monoclonal antibody conjugated commercialized by BioAtla, with a leading Phase II program in Ovarian Cancer. According...
Risk adjusted net present value: What is the current valuation of BioAtla's Mecbotamab vedotin?
Mecbotamab vedotin is a monoclonal antibody conjugated commercialized by BioAtla, with a leading Phase II program in Cervical Cancer. According...